Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD raised its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 9.2% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 380,081 shares of the company's stock after buying an additional 31,908 shares during the period. Cellebrite DI makes up approximately 1.8% of Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD's portfolio, making the stock its 17th largest position. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD owned 0.16% of Cellebrite DI worth $7,381,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. HighTower Advisors LLC purchased a new stake in shares of Cellebrite DI during the 4th quarter worth $274,000. Teacher Retirement System of Texas acquired a new stake in Cellebrite DI during the 4th quarter worth $442,000. Sei Investments Co. raised its stake in Cellebrite DI by 43.9% during the 4th quarter. Sei Investments Co. now owns 408,043 shares of the company's stock worth $8,989,000 after acquiring an additional 124,558 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in Cellebrite DI in the fourth quarter valued at $308,000. Finally, LPL Financial LLC increased its stake in Cellebrite DI by 39.0% in the fourth quarter. LPL Financial LLC now owns 54,402 shares of the company's stock valued at $1,198,000 after purchasing an additional 15,267 shares during the period. Hedge funds and other institutional investors own 45.88% of the company's stock.
Cellebrite DI Stock Down 0.8%
Shares of CLBT traded down $0.12 on Wednesday, hitting $14.37. 378,832 shares of the stock traded hands, compared to its average volume of 1,567,376. The firm has a market capitalization of $3.44 billion, a P/E ratio of -14.94, a P/E/G ratio of 2.90 and a beta of 1.28. The stock's 50 day moving average is $15.69 and its two-hundred day moving average is $18.60. Cellebrite DI Ltd. has a 1 year low of $11.90 and a 1 year high of $26.30.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.01. Cellebrite DI had a negative net margin of 46.34% and a positive return on equity of 35.36%. The business had revenue of $107.55 million for the quarter, compared to the consensus estimate of $109.36 million. During the same quarter in the prior year, the firm posted $0.08 earnings per share. The company's quarterly revenue was up 20.0% compared to the same quarter last year. Research analysts forecast that Cellebrite DI Ltd. will post 0.3 EPS for the current year.
Analyst Ratings Changes
A number of research analysts have commented on the stock. Needham & Company LLC restated a "buy" rating and issued a $24.00 price objective on shares of Cellebrite DI in a research note on Friday, June 6th. JPMorgan Chase & Co. dropped their price target on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating on the stock in a research note on Monday, May 12th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, Cellebrite DI has an average rating of "Buy" and an average price target of $22.43.
Check Out Our Latest Report on CLBT
About Cellebrite DI
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Featured Articles
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access